Spectral Med Stock Today
| EDT Stock | CAD 1.25 0.07 5.30% |
PerformanceWeakest
| Odds Of DistressRisky
|
Spectral Med is selling at 1.25 as of the 31st of January 2026; that is 5.3 percent decrease since the beginning of the trading day. The stock's open price was 1.32. Spectral Med has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 2nd of November 2025 and ending today, the 31st of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada. SPECTRAL MEDICAL operates under Diagnostics Research classification in Canada and is traded on Toronto Stock Exchange. The company has 289.14 M outstanding shares of which 394.17 K shares are currently shorted by private and institutional investors with about 6.2 days to cover all short positions. More on Spectral Med
Moving together with Spectral Stock
Moving against Spectral Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Spectral Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Spectral Med's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Spectral Med or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | ||||
Spectral Med's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Spectral Med's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsSpectral Med utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Spectral Med's leverage profile, showing how much of Spectral Med's resources are funded through borrowing.
| |||||
Spectral Med (EDT) is traded on Toronto Exchange in Canada and employs 29 people. Spectral Med is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 428.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Spectral Med's market, we take the total number of its shares issued and multiply it by Spectral Med's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Spectral Med operates under Biotechnology sector and is part of Health Care industry. The entity has 289.14 M outstanding shares of which 394.17 K shares are currently shorted by private and institutional investors with about 6.2 days to cover all short positions.
Spectral Med has accumulated about 3.8 M in cash with (8.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Spectral Med Probability Of Bankruptcy
Ownership AllocationSpectral Med shows a total of 289.14 Million outstanding shares. Spectral Med has 17.88 % of its outstanding shares held by insiders and 12.56 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Spectral Ownership Details
Spectral Med Historical Income Statement
Spectral Stock Against Markets
Spectral Stock Analysis Notes
About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.14. Spectral Med last dividend was issued on the 19th of December 2011. Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada. SPECTRAL MEDICAL operates under Diagnostics Research classification in Canada and is traded on Toronto Stock Exchange. It employs 18 people. To learn more about Spectral Med call Christopher Seto at 416 626 3233 or check out https://spectraldx.com.Spectral Med Investment Alerts
| Spectral Med generated a negative expected return over the last 90 days | |
| Spectral Med may become a speculative penny stock | |
| Spectral Med has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 2.29 M. Net Loss for the year was (15.39 M) with profit before overhead, payroll, taxes, and interest of 1.69 M. | |
| Spectral Med has accumulated about 3.8 M in cash with (8.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Spectral Medical Shares Pass Above 50-Day Moving Average - Time to Sell - MarketBeat |
Spectral Largest EPS Surprises
Earnings surprises can significantly impact Spectral Med's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-14 | 2018-06-30 | -0.01 | -0.0068 | 0.0032 | 32 | ||
2017-08-11 | 2017-06-30 | -0.01 | -0.0054 | 0.0046 | 46 | ||
2017-03-30 | 2016-12-31 | -0.01 | -0.0049 | 0.0051 | 51 |
Spectral Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 428.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Spectral Med's market, we take the total number of its shares issued and multiply it by Spectral Med's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Spectral Profitablity
Spectral Med's profitability indicators refer to fundamental financial ratios that showcase Spectral Med's ability to generate income relative to its revenue or operating costs. If, let's say, Spectral Med is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Spectral Med's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Spectral Med's profitability requires more research than a typical breakdown of Spectral Med's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.44) | (3.27) | |
| Return On Capital Employed | 0.62 | 0.65 | |
| Return On Assets | (3.33) | (3.16) | |
| Return On Equity | 0.50 | 0.53 |
Management Efficiency
Spectral Med has return on total asset (ROA) of (0.8657) % which means that it has lost $0.8657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.7397) %, meaning that it generated substantial loss on money invested by shareholders. Spectral Med's management efficiency ratios could be used to measure how well Spectral Med manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Spectral Med's Return On Capital Employed is very stable compared to the past year. As of the 31st of January 2026, Return On Equity is likely to grow to 0.53, though Return On Tangible Assets are likely to grow to (3.27). At this time, Spectral Med's Other Current Assets are very stable compared to the past year. As of the 31st of January 2026, Debt To Assets is likely to grow to 2.65, while Total Assets are likely to drop about 4.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.10) | (0.11) | |
| Tangible Book Value Per Share | (0.10) | (0.11) | |
| Enterprise Value Over EBITDA | (14.65) | (15.39) | |
| Price Book Value Ratio | (5.87) | (5.57) | |
| Enterprise Value Multiple | (14.65) | (15.39) | |
| Price Fair Value | (5.87) | (5.57) | |
| Enterprise Value | 111.6 M | 117.2 M |
Leadership effectiveness at Spectral Med is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 31st of January, Spectral Med has the Coefficient Of Variation of (1,153), variance of 6.94, and Risk Adjusted Performance of (0.06). Spectral Med technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices.Spectral Med Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Spectral Med Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Spectral Med price patterns.
Spectral Med Outstanding Bonds
Spectral Med issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spectral Med uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spectral bonds can be classified according to their maturity, which is the date when Spectral Med has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Spectral Med Predictive Daily Indicators
Spectral Med intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Spectral Med stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Spectral Med Forecast Models
Spectral Med's time-series forecasting models are one of many Spectral Med's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spectral Med's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Spectral Med without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Spectral Med Corporate Management
Elected by the shareholders, the Spectral Med's board of directors comprises two types of representatives: Spectral Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectral. The board's role is to monitor Spectral Med's management team and ensure that shareholders' interests are well served. Spectral Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectral Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sam Amory | Pres Inc | Profile | |
| BSc RN | VP Devel | Profile | |
| Blair McInnis | Chief Officer | Profile | |
| Christopher Seto | CEO Director | Profile | |
| John MD | Chief Officer | Profile |
Other Information on Investing in Spectral Stock
Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.